This recognition follows another recent honor for Mr. Kras, who was named a finalist for the Entrepreneur Of The Year® 2024 New Jersey Award by Ernst & Young (EY US). This award celebrates innovative ...
A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...
Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low ...
Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...
Hosted on MSN23d
Silexion reports breakthrough in KRAS cancer therapyThe drug is designed to inhibit several oncogenic KRAS mutations, which are prevalent in various human cancers. Mitchell Shirvan, Ph.D., Chief Scientific Officer of Silexion, expressed enthusiasm ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback